Drug
Luspatercept clinical trials
Also written ACE-536, Reblozyl and BMS-986346.
- studies test it
- 46
- open now
- 20
- in phase 3
- 11
- first study started
- 2011
Keep track of what changes. Save the luspatercept studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
46 studies that test it; most in 2022 (7)
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2013 | 2 |
| 2014 | 2 |
| 2016 | 2 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 4 |
| 2020 | 1 |
| 2021 | 3 |
| 2022 | 7 |
| 2023 | 5 |
| 2024 | 4 |
| 2025 | 6 |
| 2026 | 7 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 4
- Phase 2
- 29
- Phase 3
- 11
- Phase 4
- 4
- No phase
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 21 · Other 25
Celgene (10) · Bristol-Myers Squibb (5) · Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA (5) · Nanfang Hospital, Southern Medical University (2) · Institute of Hematology & Blood Diseases Hospital, China (2) · Peking Union Medical College Hospital (2) · M.D. Anderson Cancer Center (1) · H. Lee Moffitt Cancer Center and Research Institute (1)
Often tested with
Tested in the same studies.
Azacitidine (1) · Busulfan (1) · Cytarabine (1) · Daunorubicin (1) · Decitabine and cedazuridine drug combination (1) · CA-4948 (1) · Enasidenib (1) · Epoetin Alfa (1)
Studies
Open first, then newest update. How each study uses luspatercept is read from its arms, and is right about nine times in ten.
Testing it · 46
- MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)RecruitingPhase 2National Cancer Institute (NCI)NCT05564390Written as Luspatercept
- A Study of Luspatercept in People With AnemiaRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT07725497Written as Luspatercept
- Plasmatic Biomarkers Associated With Short-term Luspatercept Treatment of Lower Risk Myelodysplastic Syndromes (MDS) PatientsNot yet recruitingPhase 4University Hospital, GrenobleNCT07830004Written as Luspatercept
- Luspatercept + Darbepoetin in MDSRecruitingPhase 2Yale UniversityNCT07096297Written as Luspatercept
- Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-ThalassemiaRecruitingPhase 2CelgeneNCT04143724Written as ACE-536
- A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical TrialsRecruitingPhase 3CelgeneNCT04064060Written as Luspatercept
- Luspatercept for CIA in AMLRecruitingPhase 1/2Guangdong Second Provincial General HospitalNCT07663864Written as Luspatercept Injectable Product
- Luspatercept vs Epoetin in Treating Poor Erythroid Engraftment for Hematological MalignanciesNot yet recruitingPhase 2/3Nanfang Hospital, Southern Medical UniversityNCT07636486Written as Luspatercept
- Luspatercept in Preventing Poor Erythroid Engraftment for Hematological Malignancies With Moderate to Severe MyelofibrosisNot yet recruitingPhase 2/3Nanfang Hospital, Southern Medical UniversityNCT07539779Written as Luspatercept
- Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent MyelofibrosisRecruitingPhase 2GlaxoSmithKlineNCT06517875Written as Luspatercept
- Luspatercept for Clonal Cytopenias of Uncertain SignificanceRecruitingPhase 2Weill Medical College of Cornell UniversityNCT06788691Written as Luspatercept
- The Efficacy and Safety of Luspatercept in Improving Early Anemia After HSCTNot yet recruitingPhase 2Institute of Hematology & Blood Diseases Hospital, ChinaNCT07450313Written as Luspatercept
- Luspatercept for the Treatment of Anemia Following Allogeneic Hematopoietic Stem Cell Transplantation(Allo-HSCT)RecruitingPhase 1/2Zhujiang HospitalNCT07362095Written as Luspatercept
- Luspatercept in Patients Affected With Rare Inherited AnemiasNot yet recruitingPhase 2EuroBloodNet AssociationNCT07331818Written as Reblozyl
- Treatment of Transfusion-dependent Nonsevere Aplastic Anemia With Luspatercept: a Multicenter Prospective Clinical StudyNot yet recruitingNot applicableThe First Affiliated Hospital of Zhejiang Chinese Medical UniversityNCT06964971Written as Luspatercept
- AZA+Lus VS AZA Monotherapy in HR-MDSNot yet recruitingPhase 3Peking Union Medical College HospitalNCT06927232Written as Luspatercept
- Efficacy and Safety of Luspatercept for the Treatment of Anemia Due to MDS With del5q, Refractory/Resistant/Intolerant to Prior Treatments, RBC-TDRecruitingPhase 2Associazione Qol-oneNCT05924100Written as Luspatercept Injection [Reblozyl]
- The Tapering Dose of Luspatercept in Patients With Lower-risk Myelodysplastic SyndromesRecruitingPhase 2Institute of Hematology & Blood Diseases Hospital, ChinaNCT05925504Written as Luspatercept
- Efficacy of Luspatercept in ESA-naive LR-MDS Patients With or Without Ring Sideroblasts Who do Not Require TransfusionsRecruitingPhase 2University of LeipzigNCT05384691Written as Luspatercept Injection
- Clinical Observation of Luspatercept in Treatment of Chinese Adult β-thalassaemia Patients With TD β-thalassemiaRecruitingNot applicableHematology department of the 920th hospitalNCT06164821Written as luspatercept
See all 46 studies that test luspatercept →
Given in every arm · 4 — luspatercept is usual care beside what is tested
- Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESARecruitingPhase 1/2Groupe Francophone des MyelodysplasiesNCT05181735Written as Luspatercept Injection [Reblozyl]
- A Trial Comparing Three Different Treatment Options for Adults With Low-Risk Myelodysplasia and Anemia (A MyeloMATCH Treatment Trial)Not yet recruitingPhase 2National Cancer Institute (NCI)NCT07463820Written as Luspatercept
- Roxadustat Combined With Luspatercept Versus Luspatercept Monotherapy in the Treatment of Refractory MDS-RSNot yet recruitingPhase 4Peking Union Medical College HospitalNCT06006949Written as Luspatercept
- Luspatercept With or Without Hydroxyurea for the Treatment of Myelodysplastic/Myeloproliferative Neoplasms With Ring Sideroblasts and Thrombocytosis or Unclassifiable With Ring SideroblastsTerminatedPhase 2Mayo ClinicNCT05005182Written as Luspatercept
Codes
What other systems call luspatercept · ClinicalTrials.gg INT000734
- MeSH (NLM) C000621232luspaterceptConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) AQK7UBA1LSLUSPATERCEPTConfirmed FDA, NLM, Wikidata
- RxNorm 2262544Confirmed FDA, Wikidata
- Wikidata Q30314143luspaterceptConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C104012LuspaterceptOne source FDA
- DrugBank DB12281One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000621232 | luspatercept | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | AQK7UBA1LS | LUSPATERCEPT | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2262544 | — | Confirmed FDA, Wikidata |
| Wikidata | Q30314143 | luspatercept | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C104012 | Luspatercept | One source FDA |
| DrugBank | DB12281 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.